CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
I received a Biomedical Sciences degree in 2018 from the Biomedical Sciences Institute at the University of Sao Paulo. During undergrad, I spent an year as a research student at the Biology Institute, Westäflische Wilhelms-Universität Münster (WWU), sponsored by CAPES. PhD in Medicinal Chemistry and Chemical Biology at Durham University, funded by the Global Challenges Resarch Fund - Centre for Doctoral Training (GCRF-CDT), where I designed and synthesized hybrid molecules aiming to find new targets and potential drugs for leishmaniasis treatment. Currently, I am a post-doctoral researcher at IB/UNICAMP and I work with the repurposing of kinase inhibitors as potential treatments for leishmaniasis. This project is funded by Eurofarma and FINEP. I have experience with parasitology and protozoology, leishmaniasis chemotherapy, molecular biology, bioluminescente reporters and their use in drug discovery, medicinal chemistry and synthetic organic chemistry. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Protozoan parasites of the Leishmania genus are the etiological agents of leishmaniasis, diseases with diverse clinical presentations. Globally, about 2 million cases of tegumentary and visceral leishmaniasis are diagnosed every year. Only a few drugs are available for the treatment of leishmaniasis in Brazil: meglumine antimoniate, amphotericin B and pentamidine. However, these drugs pre…
| 1 / 1 | Completed scholarships in Brazil |
| Associated processes | |